Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. METHODS: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 +/- 5 kg/m(2); HbA(1c): 8.5 +/- 1.2%; 2-h PPG: 245 +/- 65 mg/dL. Patients received exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). RESULTS: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 +/- 6 mg/dL versus 208 +/- 6 mg/dL, p < 0.0001 (evaluable, N = 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 +/- 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by -76 +/- 10 mg/dL. Postprandial glucose parameters (AUC, C(ave), C(max)) were lower with exenatide than sitagliptin (p < 0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 +/- 4 mg/dL vs. -19 +/- 4 mg/dL, p = 0.3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 +/- 0.26, p = 0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 +/- 0.03, p = 0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 +/- 0.04, p = 0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 +/- 0.05, p < 0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 +/- 97 kcal vs. +130 +/- 97 kcal, p = 0.0227, N = 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. CONCLUSIONS: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [176]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“2008 Informa UK - Curr Med Res Opin 2008; 24(10) Exenatilde vs.”
Background(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Research works printed but not linked: 2
- Gedulin B, 2007, Diabetologia, 50, S239
- 2007, Endocr Pract, 13, 3
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citationBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
“pared with ExBID (31), and ExQW (23) demonstrated su-”
BackgroundMethodNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“0056] [78], whereas greater reductions were observed with exenatide once weekly, in drug-naive patients [−2.”
BackgroundGilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
“(42) conducted a double-blind, randomized, crossover, multi-center study in patients with T2DM treated with metformin.”
BackgroundKim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
“In particular, DPP-4 inhibitors effectively lower PPG by increasing active GLP-1 and decreasing glucagon levels [73].”
BackgroundA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“GLP-1 receptor agonists appear to be superior in reducing hemoglobin A1C concentrations [21] and have the added benefits of slowing the rate of gastric emptying and causing a sense of satiety leading to reduced food intake and moderate weight loss.”
InfluentialUmpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341
Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
“SITA treatment led to comparatively lesser glycemic improvement than the other agents, which supports the contention that the increase inplasmaglucagon-like peptide1 associated with dipeptidyl peptidase-4 inhibition is not as effective as pharmacological concentrations achieved with receptor agonism (15,16).”
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“Not surprisingly, their ability to augment insulin secretion and reduce HbA1c is considerably less than GLP-1 analogs (94,104,105), and they do not promote weight loss (94).”
BackgroundSelf-citationNg, B., Chu, A., & Khan, M. M. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002468 · Cited by 301
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
“One possible explanation of these differences in glucose-lowering effects relates to the greater degree of GLP-1 receptor stimulation with receptor agonists than with DPP-4 inhibitors (28).”
BackgroundAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
“One additional interesting observation comes from a crossover study in patients with T2DM and inadequate glycemic control receiving MET who were randomized to treatment with either ExBID or SITA for 2 weeks on each arm [135].”
MethodFresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 251
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Dicker, D. (2011) · Diabetes Care · doi:10.2337/dc11-s229 · Cited by 229
“COMPARISON BETWEEN GLP-1 ANALOGS AND DPP-4 INHIBITORS—In a trial comparing short-term treatment of 2 weeks with exenatide versus sitagliptin, the results were better after treatment with exenatide, as measured by several parameters: lowering postprandial glucose, increasing insulin levels, decreasing glucagon levels,…”
MethodDPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 208
“DPP-4 inhibitors are associated with a very low risk of hypoglycaemia (DeFronzo et al., 2008b) and are not linked with weight gain, gastrointestinal symptoms or peripheral oedema.”
BackgroundDPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Scheen, A. J. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.001 · Cited by 200
“In a trial comparing short-term (2-week) treatment with exeatide (5 g twice daily for 1 week, then 10 g twice daily for week) vs sitagliptin 100 mg once daily, the results were better ith exenatide treatment, as assessed in terms of lowering postrandial glucose, increasing insulin levels, decreasing glucagon evels and…”
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Okerson, T., Yan, P., Stonehouse, A., & Brodows, R. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2009.245 · Cited by 186
Self-citationPowell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
“Both liraglutide and exenatide have in short-term studies been shown to slow gastric emptying [7,38,39].”
BackgroundInfluentialKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
“Comparative data assessing the relative effects of exenatide versus sitagliptin on postprandial blood glucose [118] suggest that GLP-1 receptor agonists (perhaps due to higher mealtime concentrations of exenatide versus the levels of native GLP-1 achieved with sitagliptin) have a greater effect on postprandial glucose…”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationKim, Y. G., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12293 · Cited by 171
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
“And GLP-1R agonists were also more efficient in reducing total caloric intake [204].”
BackgroundBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 142
“GLP-1 RAs also promote satiety, decrease food intake and reduce body weight [19,20,22,23,31,32].”
BackgroundRieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., Drucker, D. J., & Vallon, V. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00259.2012 · Cited by 160
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
“In several clinical trials in T2D patients, 2-wk treatment with exenatide, a GLP-1R agonist, decreased postprandial TG (50, 180) and 4-wk treatment with vildagliptin, a DPP-4 inhibitor, reduced postprandial elevation of apoB-48 and plasma TG (132).”
BackgroundThe Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & Chilton, R. J. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 136
“This relationship may explain the observation that the DPP-4 inhibitor sitagliptin has lesser effects on postprandial glucose than exenatide, as sitagliptin yields a lower dose of GLP-1R agonist [26].”
BackgroundSelf-citationHermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
“Moreover, 2 weeks of treatment with exenatide compared to the DPP-4 inhibitor sitagliptin inhibited 2-h postprandial triglyceride and delayed gastric emptying in T2DM [13].”
BackgroundSitagliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Dhillon, S. (2010) · Drugs · doi:10.2165/11203790-000000000-00000 · Cited by 140
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
“Exenatide, derived from the saliva of the Gila monster Heloderma suspectum, has been shown to induce a dose-dependent deceleration of gastric emptying in healthy subjects [80] and type 2 diabetic patients [82, 94].”
BackgroundResultBrunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1090295 · Cited by 128
“The pharmacological concentrations of exenatide provide more GLP-1RA receptor activation than the near-physiological concentrations of GLP-1 achieved with DPP-4 inhibition [18].”
BackgroundEffects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koska, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 112
“An increasing body of clinical evidence indicates that incretin-based therapies not only lower fasting and postprandial glucose, but also improve a wide variety of traditional cardiovascular risk factors including obesity, high blood pressure as well as fasting and postprandial lipid and apolipoprotein concentrations…”
BackgroundMethodInfluentialNakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126
BOSE, M., TEIXEIRA, J., OLIVAN, B., BAWA, B., ARIAS, S., MACHINENI, S., PI‐SUNYER, F. X., SCHERER, P. E., & LAFERRÈRE, B. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00064.x · Cited by 119
Wysham, C., Bergenstal, R., Malloy, J., Yan, P., Walsh, B., Malone, J., & Taylor, K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03301.x · Cited by 118
Therapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110
“It should also be noted that a head-to-head crossover study comparing exenatide with sitagliptin has shown that, while both agents lowered the 2-h postprandial glucose levels, the overall reductionwas greaterwith exenatide and, at the end of trial, the values were in the normal range (whereas for sitagliptin, they wer…”
BackgroundGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
“The effects of exenatide and sitagliptin on postprandial glucose metabolism were compared in a randomized 2-week crossover study in patients with type 2 diabetes [47].”
BackgroundMethodResultHiramoto, B., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A., Muftah, M., Flanagan, R., & Chan, W. W. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002820 · Cited by 94
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 104
“DPP-4 inhibitors are known not to slow down gastric emptying to any meaningful extent (10, 27), and even the inhibitory effect of GLP-1 on gastric motility is subject to tachyphylaxis (28).”
BackgroundLipids, CHOs, proteins: Can all macronutrients put a ‘brake’ on eating?
Shin, H.-S., Ingram, J. R., McGill, A., & Poppitt, S. D. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.07.008 · Cited by 112
Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review
Bonaventura, A., & Montecucco, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.006 · Cited by 108
The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway
‘t Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., Alssema, M., Fadista, J., Carlotti, F., Gjesing, A. P., et al. (2013) · Diabetes · doi:10.2337/db13-0227 · Cited by 102
Best, J. H., Boye, K. S., Rubin, R. R., Cao, D., Kim, T. H., & Peyrot, M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02752.x · Cited by 97
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
The incretin hormone GLP‐1 and mechanisms underlying its secretion: 肠促胰岛素激素GLP‐1及其潜在的分泌机制
Tian, L., & Jin, T. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12439 · Cited by 94
“to 2–40h and so doubling or even tripling plasma GLP-1 concentrations.(22,25) As incretin-based drugs, DPP-4 inhibi-”
BackgroundDipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
Singh, A. K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.141319 · Cited by 101
Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.015 · Cited by 101
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 77
“Gastric emptying was also delayed to a greater extent with the GLP-1 receptor agonist compared with the DPP-4 inhibitor.(130) Modest improvements in cardiovascular risk factors such as blood pressure and lipid levels have been reported in patients treated with either DPP-4 inhibitors or GLP-1 receptor agonists.”
ResultPi-Sunyer, F. X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 86
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Regulation of chylomicron production in humans
Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 92
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0030-9 · Cited by 88
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 84
Åhrén, B., & Foley, J. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3899-2 · Cited by 82
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Potential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, C. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4039 · Cited by 74
“…directly compared, although a mechanistic study over 2 weeks indicated that while both agents had similar effects on FPG, exenatide had a greater effect on breakfast and dinner (but not lunch) postprandial glucose, 82 presumably related to the potent effect of exenatide to reduce gastric emptying.”
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Acosta, A., Camilleri, M., Burton, D., O'Neill, J., Eckert, D., Carlson, P., & Zinsmeister, A. R. (2015) · Physiological Reports · doi:10.14814/phy2.12610 · Cited by 78
“first demonstration of the persistence of marked slowing of gastric emptying at 30 days’ treatment with exenatide, demonstrated by gold standard methods, that is, radioscintigraphic emptying of a solid meal, in contrast to a prior study based on a paracetamol test (DeFronzo et al. 2008) that measures gastric emptying…”
ResultEffects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 78
Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 72
“Since sitagliptin does not delay gastric emptying (34), the intraduodenal infusion approach was not necessary in the current study.”
BackgroundLim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 76
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
“52 Finally, exenatide slowed gastric emptying and reduced caloric intake.”
InfluentialOral delivery of biologics using drug-device combinations
Caffarel–Salvador, E., Abramson, A., Langer, R., & Traverso, G. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.003 · Cited by 74
Alogliptin: a new addition to the class of DPP-4 inhibitors
Rendell, M. (2009) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s4312 · Cited by 64
“The glucose-lowering effect of currently available DPP-4 inhibitors appears to be somewhat less than those of exenatide and, unlike exenatide, there is no beneficial weight loss.(49,50) Recently a new DPP-4 inhibitor alogliptin has been developed.”
BackgroundHOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
“In this small, shortterm crossover study, exenatide resulted in lower postprandial glucose, greater increases in insulin secretion and reductions in postprandial glucagon secretion and caloric intake than sitagliptin [43].”
BackgroundStonehouse, A. H., Darsow, T., & Maggs, D. G. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
“of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia–reperfusion injury in rat heart.”
BackgroundKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
The Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
“In agreement with the effects of native GLP-1 on glucagon secretion described above, treatment with GLP-1 receptor agonists provides clear-cut reductions in glucagon [76-85].”
BackgroundChoosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
Brown, D. X., & Evans, M. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/381713 · Cited by 68
“DeFronzo and colleagues conducted a double-blind, randomized, crossover, multicentre study into the effectiveness of exenatide versus sitagliptin in subjects with T2DM currently on metformin therapy [25].”
BackgroundIncretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
The effects of weight loss strategies on gastric emptying and appetite control
Horner, K. M., Byrne, N. M., Cleghorn, G. J., Näslund, E., & King, N. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00901.x · Cited by 60
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
“For instance, vildagliptin treatment for 4 weeks lowered postprandial chylomicron TG (CM-TG) and apoB-48 (38), and sitagliptin treatment for 2 weeks decreased postprandial TG (26).”
BackgroundThe Investigation and Treatment of Diabetic Gastroparesis
Kumar, M., Chapman, A., Javed, S., Alam, U., Malik, R. A., & Azmi, S. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.012 · Cited by 68
Xie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 67
“In contrast to the GLP-1 receptor agonists, the DPP-4 inhibitors—which prolong the half-life of endogenous GLP-1—have little, if any, effect on gastric emptying [60,61].”
ResultGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Taylor, K., Gurney, K., Han, J., Pencek, R., Walsh, B., & Trautmann, M. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-9 · Cited by 64
“The GLP-1 receptor agonists (exenatide BID or QW and liraglutide) have been shown to be more efficacious at providing glycemic control and promoting weight loss than the DPP-4 inhibitors, although with more gastrointestinal side effects than with DPP-4 inhibitors [31,34,35].”
BackgroundMcCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-013-0172-6 · Cited by 65
“0001) slowed gastric emptying (sitagliptin had no effect on the rate of gastric emptying) [31].”
BackgroundResultGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Graefe-Mody, E. U., Padula, S. J., Ring, A., Withopf, B., & Dugi, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903094361 · Cited by 63
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12908 · Cited by 57
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
Kurukulasuriya, L. R., & Sowers, J. R. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-45 · Cited by 66
“Exenatide results in progressive, dose-dependant weight loss in patients with type 2 diabetes ranging from -2.8 to -5.3 kg from baseline without a plateau in effect over 3 years of therapy (n = 217, p 68 ].”
BackgroundInfluential
Metadata
- Authors
- DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA
- Eli Lilly (United States) (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- DeFronzo, Ralph A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-09-10
- Volume
- 24
- Issue
- 10
- Pages
- 2943-2952
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2159198773
- Cited by
- 373
- References
- 33
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 14 · 2019: 7 · 2018: 12 · 2017: 19 · 2016: 20 · 2015: 23 · 2014: 38 · 2013: 36 · 2012: 40
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sitagliptin, type 2 diabetes, postprandial blood glucose, insulin secretion, glucagon secretion, gastric emptying, energy intake, GLP-1 receptor agonists, DPP-4 inhibitors, insulinogenic index, metformin, glycemic control, drug comparison, fasting blood glucose
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Insulin Secretion, Blood Glucose, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Stomach, Triazoles, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.